Ionis Pharmaceuticals INC Form 4 insider transactions

Ionis Pharmaceuticals' EVP of Research, Eric Swayze, reported significant equity transactions including RSU vesting, new RSU and PRSU grants, and tax-related stock sales.

Ionis Pharmaceuticals' EVP, Chief Clinical Development Officer Eugene Schneider reported recent acquisitions and dispositions of company stock, including new RSU and PRSU grants.

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, reported the vesting of restricted stock units, a tax-related stock sale, and new grants of performance and restricted stock units.

Ionis Pharmaceuticals CEO Brett P. Monia reported the vesting of restricted stock units, a tax-related share sale, and new equity grants.

Ionis Pharmaceuticals' EVP, Chief Development Officer, Holly B. Kordasiewicz, acquired 7,500 non-qualified stock options with an exercise price of $79.67.

Ionis Pharmaceuticals' EVP, Chief Development Officer, Holly Kordasiewicz, reported the vesting of restricted stock units, a subsequent sale to cover tax obligations, and new RSU grants.

Ionis Pharmaceuticals EVP Kyle Jenne reported recent stock transactions, including RSU vesting, a tax-related stock sale, and new equity grants.

Ionis Pharmaceuticals' CFO, Elizabeth L. Hougen, reported the vesting of restricted stock units, a tax-related sale of common stock, and new grants of performance and restricted stock units.

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, reported the vesting of restricted stock units, a new grant of performance and regular restricted stock units, and a sale of shares to cover tax obligations.

Ionis Pharmaceuticals EVP Brian Birchler reported significant equity transactions, including RSU vesting, a tax-related stock sale, and new RSU and PRSU grants.

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, reported routine equity transactions including RSU vesting, a tax-related stock sale, and new performance and restricted stock unit grants.

Ionis Pharmaceuticals' Chief Business Officer, Joseph Baroldi, reported the vesting of restricted stock units and subsequent tax-related sales, alongside new equity grants.

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, sold 44,199 shares of common stock on January 7, 2026, following the exercise of stock options, all executed under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, Chief Global Product Strategy Officer, Kyle Jenne, was granted 19,350 non-qualified stock options.

Ionis Pharmaceuticals EVP of Research, Eric Swayze, exercised stock options, sold common stock, and received new option grants on January 2, 2026, under a Rule 10b5-1 plan.

Ionis Pharmaceuticals' EVP, Chief Clinical Development Officer Eugene Schneider was granted 19,350 non-qualified stock options with an exercise price of $79.67.

Ionis Pharmaceuticals granted 19,350 non-qualified stock options to EVP, CLO & General Counsel Patrick R. O'Neil with an exercise price of $79.67.

Ionis Pharmaceuticals CEO Brett P. Monia was granted 85,410 non-qualified stock options with an exercise price of $79.67, vesting over four years.

Ionis Pharmaceuticals' EVP, Chief Development Officer Holly B. Kordasiewicz, was granted 9,100 non-qualified stock options with a $79.67 exercise price.

Ionis Pharmaceuticals' EVP of Finance and CFO, Elizabeth L. Hougen, was granted 25,770 non-qualified stock options with an exercise price of $79.67.

Ionis Pharmaceuticals granted 19,350 non-qualified stock options to EVP, Chief Human Resources Officer Shannon L. Devers, with an exercise price of $79.67.

Brian Birchler, EVP of Corporate and Development Operations at Ionis Pharmaceuticals, received a grant of 19,350 non-qualified stock options with a multi-year vesting schedule.

Ionis Pharmaceuticals' EVP and Chief Scientific Officer, C. Frank Bennett, was granted 19,350 non-qualified stock options with an exercise price of $79.67.

Ionis Pharmaceuticals' Chief Business Officer, Joseph Baroldi, was granted non-qualified stock options for 21,950 shares, including options for his spouse, under the company's equity incentive plan.

Ionis Pharmaceuticals Director Joseph H. Wender sold 28,000 shares of common stock for approximately $2.2 million under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals Director Joseph Klein III exercised stock options and sold shares under a pre-arranged trading plan.

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, exercised stock options and subsequently sold a portion of her common stock holdings.

Joseph H. Wender, a director at Ionis Pharmaceuticals, exercised options to acquire 16,000 shares of common stock at $24.42 per share.

Ionis Pharmaceuticals Director Joan E. Herman exercised stock options and subsequently sold a portion of the acquired shares on November 19, 2025.

Ionis Pharmaceuticals' EVP Brian Birchler reported the sale of 8,000 shares of common stock under a pre-arranged 10b5-1 trading plan.